ANPI news
New Delhi, Dec. 29 -- USA based Afmedica Inc filed patent application for combination drug therapy for reducing scar tissue formation. The inventors are Shebuski Ronald J, Ludere Jack R and Fischell Tim A.
Afmedicainc filed the patent application on Dec. 26, 2006. The patent application number is 3904/KOLNP/2006 A. The international classification numbers are A61K31/4745 and A61F2/00.
According to the Controller General of Patents, Designs & Trade Marks, "The present invention describes various devices and methods wherein a cytostatic antiproliferative drug, either alone or in combination with other drugs, is placed between internal body tissues to prevent the formation of scar tissue and/or adhesions during healing of a wound or surgical site. Specific devices to achieve this administration include, but are not limited to, a permanent implant or a biodegradable material having an attached antiproliferative drug such as sirolimus. These antiproliferative drugs may be combined with other drugs including, but not limited to, antiplatelets, antithrombotics or anticoagulants. The present invention also contemplates methods to a reduce scar tissue and/or adhesions or adhesion formation at an anastomosis site. In particular, a cytostatic antiproliferative drug is administered to an arteriovenous shunt anastomoses in patients having end- stage renal disease."
Afmedica, Inc., a life-sciences company, focuses on drug/device products to prevent cardiovascular complications that occur following surgery. The company engages in commercializing anti-proliferative cyto-static drugs, such as sirolimus on various devices for the prevention of scar tissue formation after surgical procedures. It also develops perivascular technology using the drug rapamycin to treat peripheral vascular, coronary artery, and end stage renal diseases. The company was founded in 2002 and is based in Kalamazoo, Michigan. As of October 7, 2005, Afmedica, Inc. operates as a subsidiary of Angiotech Pharmaceuticals, Inc.
